DOJ Defends Cannabis Rescheduling Against Industry Opposition
Justice Department pushes back on drug testing and pharma companies trying to halt marijuana rescheduling, citing financial motives behind legal challenges.
The Department of Justice filed a federal court brief defending the cannabis rescheduling process against attempts by drug testing companies and pharmaceutical firms to halt the regulatory change. The government's filing directly challenges opponents' motives, arguing that industry groups seeking to block rescheduling are primarily driven by financial interests rather than public health concerns.
The legal pushback comes as the Trump administration's cannabis rescheduling proposal faces coordinated opposition from established industries that profit from marijuana's current Schedule I status. Drug testing companies generate substantial revenue from workplace cannabis screening programs, while certain pharmaceutical companies view rescheduled marijuana as potential competition for their products treating similar conditions.
The DOJ's aggressive defense of the rescheduling timeline signals strong federal commitment to moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. This regulatory shift would reduce federal penalties, enable tax deductions for cannabis businesses under Section 280E, and potentially unlock banking services for the industry. The change could add billions in value to cannabis companies currently operating under restrictive federal classifications.
Industry observers view the government's willingness to directly confront opposition groups as a positive indicator for rescheduling momentum. The brief's language suggests federal agencies recognize the economic stakes involved and are prepared to counter arguments that prioritize incumbent industry profits over policy reform. This stance could accelerate the regulatory timeline if courts reject delay tactics.
The legal maneuvering highlights broader tensions as traditional industries adapt to cannabis normalization. Drug testing companies face potential revenue declines if workplace policies shift away from zero-tolerance marijuana screening, while pharmaceutical firms confront new competition in pain management and other therapeutic areas. The DOJ's defense of rescheduling suggests federal policymakers increasingly view these concerns as secondary to broader cannabis policy reform objectives.